Safety considerations for new vaccine development

被引:19
作者
Ellenberg, SS [1 ]
机构
[1] US FDA, Off Biostat & Epidemiol, Ctr Biol Evaluat & Res, Rockville, MD 20857 USA
关键词
vaccine; clinical trials; adverse events; spontaneous reports; post-market surveillance;
D O I
10.1002/pds.616
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Vaccines are highly effective and extremely safe. Although most known vaccine reactions are minor (e.g. fever, injection site pain or swelling), rare but serious reactions such as vaccine-associated paralytic polio do occur. When large populations are vaccinated, some adverse health events may occur by chance shortly after vaccination. It is difficult to determine whether these are truly coincidental or attributable to the vaccine. The most reliable way to assess causality is in a controlled study, but clinical trials of new vaccines are typically too small to detect rare but serious effects. If the size of these trials were increased, much more could be learned about the safety of a vaccine prior to its exposure to entire populations. This information would increase confidence in the safety of vaccines, would be a valuable resource for assessing spontaneous reports of adverse events after licensure, and would reduce the risk of licensing a new vaccine that had the potential to cause severe injury to a small proportion of vaccinees. Published in 2001 by John Wiley & Sons, Ltd.
引用
收藏
页码:411 / 415
页数:5
相关论文
共 16 条